---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-080058"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2026-07-02T10:20:28+00:00"
generated_at: "2026-07-02T10:25:04.813703+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Elicio Therapeutics prices $15M registered direct offering of 4.38M shares at $3.43/share

## Summary
- Offering of 4,380,313 shares of common stock at $3.43 per share for gross proceeds of ~$15M.
- Two new institutional investors and a large existing shareholder participated; expected close July 6, 2026.
- Net proceeds to fund Phase 1 clinical development of ELI-002 7P in metastatic PDAC and pipeline/platform.
- Titan Partners (lead) and B. Riley Securities (co-placement agent) acted as placement agents.
- Offering made under effective shelf registration statement (File No. 333-293861).

## SEC filing metadata
- accession: 0001104659-26-080058
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2026-07-02T10:20:28+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000110465926080058/0001104659-26-080058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000110465926080058/tm2619637d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-080058
- JSON: https://secwatch.observer/filing/0001104659-26-080058.json
- Plain text: https://secwatch.observer/filing/0001104659-26-080058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.